GI
NAGE

GAMMA Investing’s Niagen Bioscience NAGE Stock Holding History

GAMMA Investing’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14K Sell
358
-107
-23% -$434 ﹤0.01% 3854
2026
Q1 		$2.05K Sell
465
-326
-41% -$1.76K ﹤0.01% 3659
2025
Q4 		$5.03K Buy
791
+190
+32% +$1.32K ﹤0.01% 3266
2025
Q3 		$5.61K Buy
601
+6
+1% +$61 ﹤0.01% 3133
2025
Q2 		$8.57K Buy
595
+55
+10% +$543 ﹤0.01% 2880
2025
Q1 		$3.73K Buy
540
+495
+1,100% +$3.11K ﹤0.01% 3203
2024
Q4 		$239 Buy
+45
New +$246 ﹤0.01% 3693

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

GAMMA Investing's NAGE Position: Q2 2026 in Review

GAMMA Investing reduced its Niagen Bioscience (NAGE) stake by 23% in Q2 2026, selling an estimated $434 and leaving 358 shares worth $1.14K. The position accounts for ﹤0.01% of the portfolio, ranked #3854.

GAMMA Investing first reported a position in NAGE in Q4 2024 and has held it in 7 quarters since. The position peaked at $8.57K in Q2 2025. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • GAMMA Investing held 358 shares of Niagen Bioscience worth $1.14K as of Q2 2026.
  • GAMMA Investing sold 107 Niagen Bioscience shares in Q2 2026, an estimated $434.
  • Niagen Bioscience made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3854 holding.
  • GAMMA Investing first reported a position in Niagen Bioscience in Q4 2024 and has held it in 7 quarters since.
  • GAMMA Investing's Niagen Bioscience position peaked at $8.57K in Q2 2025.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.